Indeed, insulin therapy increased cEPCs levels (CD133+KDR+/CD34+CD133+KDR+) in T2DM patients after 6 months of treatment alternating basal insulin analogues glargine and detemir [160], and a 4-months-treatment of T2DM patients with either, insulin glargine or NPH insulin increased the outgrowth of EPCs (CD34+ KDR+) in comparison with oral medication [161]. Here, CD34 is linked to type 2 diabetes mellitus.